• By Joe Dangor

Mayo Clinic enrolls first patient in phase 1 study of orally delivered capsule to treat recurrent Clostridium difficile infection

January 18, 2017

Illustration of Human Digestive SystemROCHESTER, Minn. – Mayo Clinic announced today that it has enrolled the first patient in a phase one study of a unfrozen oral capsule formulated to treat Clostridium difficile infection.

The capsule is formulated to rehabilitate the human gut microbiome delivering a broad spectrum of live microbes into the patient's intestinal tract. The gut microbiome hosts trillions of microbes that live in harmony with their human host and perform processes vital for health.

“New therapies are urgently needed to prevent recurrent C-diff, a debilitating, costly and potentially life-threatening infection," says Sahil Khanna, M.B.B.S., a gastroenterologist at Mayo Clinic and principal investigator on the study. He says the study will enroll approximately 20 patients in a prospective, two-arm, phase-one, safety assessment and dosing study at Mayo Clinic’s Rochester campus.

MEDIA CONTACT: Joe Dangor, Mayo Clinic Public Affairs, 507-284-5005, newsbureau@mayo.edu

“C-diff infections are an increasingly difficult-to-resolve intestinal infection that cause about 29,000 deaths annually in the U.S.,” says Dr. Khanna.

Dr. Khanna says potential advantages to providing an oral capsule for treatment that is stable at room temperature include flexibility in dosing and at-home treatment. Currently, patients seeking treatment must travel to a medical center for a fecal transplant procedure that involves the placement of live microbes into the patient's body in a procedure similar to a colonoscopy.

###

About Mayo Clinic
Mayo Clinic is a nonprofit organization committed to clinical practice, education and research, providing expert, whole-person care to everyone who needs healing. For more information, visit http://www.mayoclinic.org/about-mayo-clinic or https://newsnetwork.mayoclinic.org/.